JP2000513340A5 - - Google Patents

Download PDF

Info

Publication number
JP2000513340A5
JP2000513340A5 JP1998501656A JP50165698A JP2000513340A5 JP 2000513340 A5 JP2000513340 A5 JP 2000513340A5 JP 1998501656 A JP1998501656 A JP 1998501656A JP 50165698 A JP50165698 A JP 50165698A JP 2000513340 A5 JP2000513340 A5 JP 2000513340A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998501656A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000513340A (ja
JP5000793B2 (ja
Filing date
Publication date
Priority claimed from GBGB9612297.3A external-priority patent/GB9612297D0/en
Application filed filed Critical
Publication of JP2000513340A publication Critical patent/JP2000513340A/ja
Publication of JP2000513340A5 publication Critical patent/JP2000513340A5/ja
Application granted granted Critical
Publication of JP5000793B2 publication Critical patent/JP5000793B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP50165698A 1996-06-11 1997-06-02 医用ホルモテロールエアゾール製剤 Expired - Lifetime JP5000793B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9612297.3A GB9612297D0 (en) 1996-06-11 1996-06-11 Medicinal aerosol formulations
GB9612297.3 1996-06-11
PCT/US1997/009471 WO1997047286A1 (en) 1996-06-11 1997-06-02 Medicinal aerosol formulations of formoterol

Publications (3)

Publication Number Publication Date
JP2000513340A JP2000513340A (ja) 2000-10-10
JP2000513340A5 true JP2000513340A5 (cg-RX-API-DMAC10.html) 2005-02-10
JP5000793B2 JP5000793B2 (ja) 2012-08-15

Family

ID=10795182

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50165698A Expired - Lifetime JP5000793B2 (ja) 1996-06-11 1997-06-02 医用ホルモテロールエアゾール製剤

Country Status (16)

Country Link
EP (2) EP1400239A1 (cg-RX-API-DMAC10.html)
JP (1) JP5000793B2 (cg-RX-API-DMAC10.html)
AR (1) AR009231A1 (cg-RX-API-DMAC10.html)
AT (1) ATE275940T1 (cg-RX-API-DMAC10.html)
AU (1) AU726382B2 (cg-RX-API-DMAC10.html)
CA (1) CA2257841C (cg-RX-API-DMAC10.html)
DE (1) DE69730723T2 (cg-RX-API-DMAC10.html)
DK (1) DK0934057T3 (cg-RX-API-DMAC10.html)
ES (1) ES2229366T3 (cg-RX-API-DMAC10.html)
GB (1) GB9612297D0 (cg-RX-API-DMAC10.html)
ID (1) ID19520A (cg-RX-API-DMAC10.html)
NO (1) NO320403B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ333202A (cg-RX-API-DMAC10.html)
PT (1) PT934057E (cg-RX-API-DMAC10.html)
WO (1) WO1997047286A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA974546B (cg-RX-API-DMAC10.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6423298B2 (en) * 1998-06-18 2002-07-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical formulations for aerosols with two or more active substances
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
DE19847969A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
EP1121112B1 (de) * 1998-10-17 2002-06-05 Boehringer Ingelheim Pharma KG Lagerfähiges wirkstoffkonzentrat mit formoterol
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6290930B1 (en) 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
UA73986C2 (uk) 2000-05-22 2005-10-17 К'Єзі Фармачеутічі С.П.А. АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ
SE0004750D0 (sv) * 2000-12-19 2000-12-19 Astrazeneca Ab Novel formulation
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
DE60103527T2 (de) 2001-07-02 2005-06-16 Chiesi Farmaceutici S.P.A. Optimierte Tobramycin-Formulierung zur Aerosolbildung
AR036358A1 (es) * 2001-08-28 2004-09-01 Schering Corp Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
GB0207899D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and cielesonide aerosol formulations
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
WO2004020289A1 (en) 2002-08-27 2004-03-11 Schering Corporation Process for producing metered dose inhaler formulations
EP1635845A1 (en) * 2003-06-13 2006-03-22 ALTANA Pharma AG Formoterol and ciclesonide combination
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
CA2542530A1 (en) * 2003-10-20 2005-05-12 Schering Corporation Pharmaceutical aerosol compositions
EP1925293A3 (en) * 2003-10-20 2010-01-13 Schering Corporation Pharmaceutical aerosol compositions
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
ES2398480T3 (es) * 2006-10-17 2013-03-19 Lithera, Inc. Procedimientos, composiciones, y formulaciones para el tratamiento de la enfermedad ocular tiroidea
PL2435024T3 (pl) * 2009-05-29 2017-01-31 Pearl Therapeutics, Inc. Dostarczanie substancji czynnych do dróg oddechowych oraz powiązane sposoby i systemy
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
DK2727582T3 (en) * 2009-10-02 2016-05-17 Chiesi Farma Spa Pharmaceutical aerosol formulations of formoterol and beclomethasone dipropionate
CA2905542C (en) 2013-03-15 2022-05-03 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05508616A (ja) * 1989-02-23 1993-12-02 ローヌー プーラン ローラー インターナショナル(ホウルディングス)インコーポレイテッド 治療用エアロゾル剤
IL97065A (en) * 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
GB9024365D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
EP0504112A3 (en) * 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
SK140493A3 (en) * 1991-06-10 1994-10-05 Schering Corp Non-chlorofluorocarbon aerosol formulations
YU59192A (sh) * 1991-06-10 1994-12-28 Schering Corporation Formulacija aerosola koje ne sadrže hlorofluorougljenična jedinjenja
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
ATE128350T1 (de) * 1991-12-12 1995-10-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung.
EP1086688B1 (en) * 1991-12-18 2004-03-03 Minnesota Mining And Manufacturing Company Suspension aerosol formulations
GB9207400D0 (en) * 1992-04-02 1992-05-13 Smithkline Beecham Plc Novel use
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
GB9425160D0 (en) * 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition

Similar Documents

Publication Publication Date Title
JP2000502280A5 (cg-RX-API-DMAC10.html)
JP2000501771A5 (cg-RX-API-DMAC10.html)
JP2000501599A5 (cg-RX-API-DMAC10.html)
JP2000501018A5 (cg-RX-API-DMAC10.html)
JP2000500076A5 (cg-RX-API-DMAC10.html)
JP2000501324A5 (cg-RX-API-DMAC10.html)
JP2000500055A5 (cg-RX-API-DMAC10.html)
JP2000502472A5 (cg-RX-API-DMAC10.html)
JP2000501825A5 (cg-RX-API-DMAC10.html)
JP2000501338A5 (cg-RX-API-DMAC10.html)
JP2000500874A5 (cg-RX-API-DMAC10.html)
JP2000502425A5 (cg-RX-API-DMAC10.html)
JP2000502485A5 (cg-RX-API-DMAC10.html)
JP2000502568A5 (cg-RX-API-DMAC10.html)
JP2000501774A5 (cg-RX-API-DMAC10.html)
JP2000500912A5 (cg-RX-API-DMAC10.html)
JP2000502570A5 (cg-RX-API-DMAC10.html)
JP2000501876A5 (cg-RX-API-DMAC10.html)
JP2000501744A5 (cg-RX-API-DMAC10.html)
JP2000513340A5 (cg-RX-API-DMAC10.html)
JP2000501229A5 (cg-RX-API-DMAC10.html)
JP2000502316A5 (cg-RX-API-DMAC10.html)
JP2000500857A5 (cg-RX-API-DMAC10.html)
JP2000502714A5 (cg-RX-API-DMAC10.html)
JP2000501569A5 (cg-RX-API-DMAC10.html)